These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 27038531)
1. The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells. Montani M; Pazmay GVB; Hysi A; Lupidi G; Pettinari R; Gambini V; Tilio M; Marchetti F; Pettinari C; Ferraro S; Iezzi M; Marchini C; Amici A Pharmacol Res; 2016 May; 107():282-290. PubMed ID: 27038531 [TBL] [Abstract][Full Text] [Related]
2. In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model. Mendes N; Tortosa F; Valente A; Marques F; Matos A; Morais TS; Tomaz AI; Gärtner F; Garcia MH Anticancer Agents Med Chem; 2017; 17(1):126-136. PubMed ID: 27671310 [TBL] [Abstract][Full Text] [Related]
3. Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model. Miachin K; Del Solar V; El Khoury E; Nayeem N; Khrystenko A; Appelt P; Neary MC; Buccella D; Contel M Inorg Chem; 2021 Dec; 60(24):19152-19164. PubMed ID: 34846878 [TBL] [Abstract][Full Text] [Related]
4. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells. Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527 [TBL] [Abstract][Full Text] [Related]
5. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells. Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of anticancer role of a novel ruthenium(II)-based compound compared with NAMI-A and cisplatin in impairing mitochondrial functionality and promoting oxidative stress in triple negative breast cancer models. Silvestri S; Cirilli I; Marcheggiani F; Dludla P; Lupidi G; Pettinari R; Marchetti F; Di Nicola C; Falcioni G; Marchini C; Orlando P; Tiano L; Amici A Mitochondrion; 2021 Jan; 56():25-34. PubMed ID: 33220497 [TBL] [Abstract][Full Text] [Related]
7. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands. Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875 [TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. Frik M; Martínez A; Elie BT; Gonzalo O; Ramírez de Mingo D; Sanaú M; Sánchez-Delgado R; Sadhukha T; Prabha S; Ramos JW; Marzo I; Contel M J Med Chem; 2014 Dec; 57(23):9995-10012. PubMed ID: 25409416 [TBL] [Abstract][Full Text] [Related]
9. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701 [TBL] [Abstract][Full Text] [Related]
10. Ruthenium metallodendrimer against triple-negative breast cancer in mice. Michlewska S; Wójkowska D; Watala C; Skiba E; Ortega P; de la Mata FJ; Bryszewska M; Ionov M Nanomedicine; 2023 Sep; 53():102703. PubMed ID: 37591367 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells. Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246 [TBL] [Abstract][Full Text] [Related]
12. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes. Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392 [TBL] [Abstract][Full Text] [Related]
13. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361 [TBL] [Abstract][Full Text] [Related]
14. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells. Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087 [TBL] [Abstract][Full Text] [Related]
15. Discovery of high in vitro and in vivo antitumor activities of organometallic ruthenium(ii)-arene complexes with 5,7-dihalogenated-2-methyl-8-quinolinol. Meng T; Qin QP; Chen ZL; Zou HH; Wang K; Liang FP Dalton Trans; 2019 Apr; 48(16):5352-5360. PubMed ID: 30942794 [TBL] [Abstract][Full Text] [Related]
16. Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage. Furrer MA; Schmitt F; Wiederkehr M; Juillerat-Jeanneret L; Therrien B Dalton Trans; 2012 Jun; 41(24):7201-11. PubMed ID: 22506276 [TBL] [Abstract][Full Text] [Related]
17. A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity. Karki K; Wright GA; Mohankumar K; Jin UH; Zhang XH; Safe S Cancer Res; 2020 Mar; 80(5):1011-1023. PubMed ID: 31911554 [TBL] [Abstract][Full Text] [Related]
18. Effects of some ruthenium chelates on MCa mammary carcinoma and on TLX5 lymphoma in mice. Bregant F; Pacor S; Ghosh S; Chattopadhyay SK; Sava G Anticancer Res; 1993; 13(4):1011-7. PubMed ID: 8352519 [TBL] [Abstract][Full Text] [Related]
19. Transport of the Ruthenium Complex [Ru(GA)(dppe) Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527 [TBL] [Abstract][Full Text] [Related]
20. Arene-Ru(II) complexes of curcumin exert antitumor activity via proteasome inhibition and apoptosis induction. Bonfili L; Pettinari R; Cuccioloni M; Cecarini V; Mozzicafreddo M; Angeletti M; Lupidi G; Marchetti F; Pettinari C; Eleuteri AM ChemMedChem; 2012 Nov; 7(11):2010-20. PubMed ID: 22997162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]